GlassScriptPhysician profile
Megumi M Vogt
NPI 1366429367
$3,805.57
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,022 · 2020: $932 · 2021: $730 · 2022: $79.08 · 2023: $42.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $42.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $42.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $425.78 | 2019-2021 | |
| Allergan, INC. | $316.01 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $299.05 | 2019-2020 | |
| Csl Behring | $270.75 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $236.80 | 2019-2021 | |
| Biogen, INC. | $229.87 | 2019-2023 | Vumerity |
| Novartis Pharmaceuticals Corporation | $199.39 | 2019-2020 | |
| Emd Serono, INC. | $197.63 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $170.97 | 2020-2021 | |
| Ucb, INC. | $161.98 | 2019-2021 | |
| Adamas Pharmaceuticals, INC. | $93.06 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $92.69 | 2020-2021 | |
| Eisai INC. | $90.35 | 2019-2021 | |
| Neurelis, INC. | $87.61 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $74.21 | 2019 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megumi Vogt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.